Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 5 | 230 | 44% |
| 2020 | 2 | 213 | 46% |
| 2021 | 3 | 156 | 49% |
| 2022 | 4 | 176 | 51% |
| 2023 | 3 | 166 | 53% |
| 2024 | 3 | 152 | 54% |
| 2025 from claims | – | 156 126–183 | 55% |
| 2026 forecast | – | 159 124–199 | 55% |
| 2027 forecast | – | 161 119–213 | 56% |
| 2028 forecast | – | 163 115–225 | 56% |
| 2029 forecast | – | 165 112–237 | 57% |
| 2030 forecast | – | 167 110–248 | 57% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Arizona; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 11 | 827+0.6%/yr | +0.6%/yr | 0.2 | 0% | 910 in 2030+1.5%/yr |
| Washington | 1 | 140−4.3%/yr | −4.3%/yr | 0.2 | 0% | 140 in 2030+0.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 12 | 342+14%/yr | +14%/yr | 0.51.0× | 0% | 770 in 2030+14%/yr |
| DBS & VNS | 4 | 305−10%/yr | −10%/yr | 0.41.3× | 0% | 540 in 2030+9.8%/yr |
| Stroke thrombectomy | 10 | 233+2.7%/yr | +2.7%/yr | 0.30.8× | 0% | 280 in 2030+3%/yr |
CSF shunts in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Johnson & Johnson MedTech leads with 51% of company spending on these surgeons in 2025, −28 pts on 2024.
In 2025, 6 companies reported engagement with Arizona’s surgeons worth $4,382 in consulting, speaking, meals and travel tied to these products, about $1,461 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.